This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           October 01, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store


Adding cediranib to chemo improves progression-free survival for metastatic or recurrent cervical cancer, phase II trial shows
Medical News Today
For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumor shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Practice Survey deadline extended to Oct. 13
Full and Candidate Members: The deadline has been extended to Oct. 13 to take SGO’s Practice Survey. If you missed the email with your personal link to the survey, please click here. Robust results may help you negotiate a higher salary. Those who complete the survey will receive the 2015 State of the Subspecialty report at no charge.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


BAM: A major cause of diarrhea in cancer patients
Clinical Oncology
Poor absorption of bile acid is the cause of chronic diarrhea in a large proportion of cancer patients, new research shows. The study of 506 patients with diarrhea and a variety of cancer types found that 43 percent had bile acid malabsorption (BAM), suggesting an opportunity to substantially improve quality of life in patients with this complication. The study provides the basis for a more focused approach to diarrhea in cancer patients, said Frank Phillips, MD, a trainee gastroenterologist at the Royal Marsden Hospital, in London, England, who presented the study at Digestive Disease Week 2014.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.


Gelsolin plays role in destroying chemo-resistant ovarian cancer cells
Medical News Today
Gelsolin (GSN) is an important etiologic factor in chemoresistance in vitro, researchers reported recently in the Proceedings of the National Academy of Sciences. They also concluded that the application of C-terminal GSN may represent a new therapeutic strategy for chemoresistant gynecologic cancer. The in vitro findings were also validated with a clinical investigation that determines the relationship between GSN expression and cis-Diammine dichloroplatinium (II) sensitivity in human ovarian tumor.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Ovarian cancer oncogene found in 'junk DNA'
Oncology Nurse Advisor
A research team mined junk DNA sequences to identify a non-protein-coding RNA whose expression is linked to ovarian cancer in a study published in Cancer Cell. The researchers built a DNA copy number profile for nearly 14,000 long noncoding RNAs, or lncRNAs across 12 cancer types, including ovarian and breast cancers that include the two major BRCA-related cancers. They found that the number of copies of lncRNA genes on a chromosome consistently changes in the 12 different cancer types. Also, lncRNA genes are widely expressed in cancer cells.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Work for the best
We are seeking a gyn-oncologist to join our growing health system in Springfield, Mo. Our clinic has on-site lab and radiology services, access to a da Vinci® surgical robot and a strong support staff. For more information about this opportunity at our physician owned and operated clinic, call 1-800-869-4201. MORE
Exceptional Care, Close to Home

21st Century Oncology – the nation’s largest cancer treatment network and global leader in cancer care – providing integrated clinical teams treating patients collaboratively to improve outcomes.


Pertuzumab 'unprecedented' in extending lives
FOX News
A new breast cancer drug, pertuzumab, has shown "unprecedented" benefits in extending lives in a clinical trial and experts urged its widespread use for women with an aggressive form of the disease. Patients with a type of breast cancer known as HER2 positive, which makes up about a quarter of all breast cancers, who were given Perjeta on top of older medicine Herceptin and chemotherapy lived 15.7 months longer than those on Herceptin and chemotherapy alone.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

New technique could improve the outcome of breast cancer surgery
Medical Xpress
A new technique will help surgeons to detect where the margins of cancerous breast tumors are during surgery, reducing the need for secondary operations in breast cancer patients. Scientists have developed a highly accurate prototype technique which can produce a detailed 'molecular fingerprint' of breast tissues removed during surgery. This technique – which can produce detailed maps of the tissue - has the potential to improve the outcome for breast cancer surgery and to reduce unnecessary secondary operations, according to the study published in Physics in Medicine and Biology.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


New IBD research connects Crohn's disease with cervical neoplasia
Inflammatory Bowel Disease News Today
A recent study published in Clinical Gastroenterology and Hepatology reported a new link between Crohn’s disease (CD) and uterine cervix neoplastic lesions. The researchers commented: “Women with a diagnosis of CD had increased risk of cervical dysplasia and cancer despite similar screening intensity as in the general population. Patients with UC only had increased risk of dysplasia along with a slightly increased screening frequency compared to controls. Patients with IBD should be encouraged to follow the screening program for cervical neoplasia and clinicians should be aware of the slightly increased risk of HPV-related cervical lesions in IBD patients.”
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Fusion of CTLA-4 with HPV16 E7 and E6 enhanced potency of therapeutic HPV DNA vaccine
Using CTLA-4 with E7 and E6 can enhance cellular and humoral immune responses against HPV16, according to a study published Sept. 29 in PLOS One. This strategy may provide useful ideas for developing therapeutic HPV DNA vaccines. However, further studies are needed to optimize the strategy.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news

Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Sept. 24, 2014
Sept. 17, 2014
Sept. 10, 2014
Aug. 27, 2014

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063